Catalyst Wire Dossier Catalyst Wire Dossier
CLINICAL_TRIALS trial_result · 2024-12-16

Clinical Trial Update: Ixazomib and Rituximab in Treating Patients With Relapsed or Refractory Mantle Cell Lymphoma [Phase 2]

View source ↗

Summary

A Phase 2 study evaluating ixazomib in combination with rituximab for relapsed or refractory mantle cell lymphoma was terminated, with results posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

Drugs mentioned

  • Rituximab (rituximab)
  • ixazomib (ixazomib)

Snippet

Sponsor: M.D. Anderson Cancer Center | Conditions: Recurrent Mantle Cell Lymphoma, Refractory Mantle Cell Lymphoma | Phase 2 | Status: TERMINATED | Results posted: 2024-12-16